May 22, 2019 / 01:00PM GMT
Dan Brennand - UBS Investment Bank, Research Division
Welcome. Day 3 of the UBS Global Healthcare Conference. My name is Dan Brennand. I cover tools, diagnostics and the pharma service space. Very pleased to have with me on stage Chuck Kummeth, CEO of Bio-Techne. In the audience, we have David Clair as well from IR.
Listen, we are going to have a series of questions to go through with Chuck, and certainly, we welcome any audience participation. So during the presentation, I'll look up and feel free to just chime in. But before we do that, I need to point everyone to the UBS website, www.ubs.com, to look for analyst disclaimers.
So with that, Chuck, welcome. Very pleased to have you here. I thought we could just start out, Chuck, just by talking about Bio-Techne's overall growth profile. I know you've discussed kind of the double-digit growth profile as a target. I think growth year-to-date has been around that level. Just kind of wondering -- well, I don't know if you wanted to go through the slides first.
Bio-Techne Corp at UBS Global Healthcare Conference Transcript
May 22, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers